Rankings
▼
Calendar
TBPH Q3 2024 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena
TBPH
Theravance Biopharma, Inc.
$716M
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$17M
+7.5% YoY
Gross Profit
$8M
45.1% margin
Operating Income
-$11M
-64.2% margin
Net Income
-$13M
-75.3% margin
EPS (Diluted)
$-0.26
QoQ Revenue Growth
+18.3%
Cash Flow
Operating Cash Flow
-$5M
Free Cash Flow
-$5M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$356M
Total Liabilities
$170M
Stockholders' Equity
$186M
Cash & Equivalents
$23M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$17M
$16M
+7.5%
Gross Profit
$8M
$14M
-47.1%
Operating Income
-$11M
-$9M
-23.7%
Net Income
-$13M
-$9M
-41.9%
Revenue Segments
YUPELRI Monotherapy
$22M
56%
Collaboration revenue
$17M
44%
← FY 2024
All Quarters
Q4 2024 →